Download PDF
Facial Plast Surg 2018; 34(02): 119-127
DOI: 10.1055/s-0038-1637004
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Rejuvenation of the Upper Face and Brow: Neuromodulators and Fillers

Jessyka G. Lighthall
1   Division of Otolaryngology-Head & Neck Surgery, Penn State Hershey Medical Center, Hershey, Pennsylvania
› Author Affiliations
Further Information

Publication History

Publication Date:
09 April 2018 (online)

Also available at
    Permissions and Reprints

Abstract

Facial aging involves a combination of volume loss and descent, loss of skin elasticity, dynamic lines due to facial mimetic muscle action, and development of static rhytids. Although surgery remains an option for treatment, minimally invasive aesthetic procedures continue to gain popularity with the use of neuromodulators and soft tissue fillers being the most sought-after procedures. Although these may be used in isolation to treat specific concerns, they are often combined to address multiple facets of aging. Multiple different neuromodulators and fillers are commercially available. Although relatively effective and safe, a thorough understanding of their indications, compositions, and potential adverse effects is paramount. This article will review the available aesthetic products for minimally invasive periorbital rejuvenation with botulinum toxin and injectable fillers. Although it will not focus on other therapies aimed at facial rejuvenation, such as resurfacing techniques or surgical interventions, it is important to note that an individualized treatment plan may combine multiple therapies to optimize patient outcomes and satisfaction.

Keywords

neuromodulator - filler - brow - periocular - facial aging
 

  • References

  • 1 American Society of Plastic Surgeons. 2016 Plastic Surgery Statistics Report. Available at: https://www.plasticsurgery.org/documents/News/Statistics/2016/plastic-surgery-statistics-full-report-2016.pdf . Accessed December 1, 2017
    PubMed
  • 2 Fitzgerald R. Contemporary concepts in brow and eyelid aging. Clin Plast Surg 2013; 40 (01) 21-42
    CrossrefPubMedGoogle Scholar
  • 3 Maas CS. Botulinum neurotoxins and injectable fillers: minimally invasive management of the aging upper face. Facial Plast Surg Clin North Am 2006; 14 (03) 241-245
    CrossrefPubMedGoogle Scholar
  • 4 Kikkawa DOLB. Orbit and eyelid anatomy. In: Press R. , ed. Ophthalmic Plastic Surgery: Prevention and Management of Complications. New York, NY: Raven Press; 1994
    Google Scholar
  • 5 Zide BM, Ovid Technologies I. Surgical Anatomy Around the Orbit: The System of Zones. Philadelphia, PA: Lippincott Williams & Wilkins; 2006
    Google Scholar
  • 6 Dutton JJ. Atlas of Clinical and Surgical Orbital Anatomy. 2nd ed. Philadelphia, PA: Elsevier Saunders; 2011
    Google Scholar
  • 7 Mendelson BC, Muzaffar AR, Adams Jr WP. Surgical anatomy of the midcheek and malar mounds. Plast Reconstr Surg 2002; 110 (03) 885-896 , discussion 897–911
    CrossrefPubMedGoogle Scholar
  • 8 Moon HS, Ahn B, Lee JH, Rah DK, Park TH. Rejuvenation of the deep superior sulcus in the eyelid. J Cosmet Dermatol 2016; 15 (04) 458-468
    CrossrefPubMedGoogle Scholar
  • 9 Gart MS, Gutowski KA. Overview of botulinum toxins for aesthetic uses. Clin Plast Surg 2016; 43 (03) 459-471
    CrossrefPubMedGoogle Scholar
  • 10 Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev 2000; 80 (02) 717-766
    CrossrefPubMedGoogle Scholar
  • 11 Erickson BP, Lee WW, Cohen J, Grunebaum LD. The role of neurotoxins in the periorbital and midfacial areas. Facial Plast Surg Clin North Am 2015; 23 (02) 243-255
    CrossrefPubMedGoogle Scholar
  • 12 Cavallini M, Cirillo P, Fundarò SP. , et al. Safety of botulinum toxin A in aesthetic treatments: a systematic review of clinical studies. Dermatol Surg 2014; 40 (05) 525-536
    CrossrefPubMedGoogle Scholar
  • 13 Yang GC, Chiu RJ, Gillman GS. Questioning the need to use Botox within 4 hours of reconstitution: a study of fresh vs 2-week-old Botox. Arch Facial Plast Surg 2008; 10 (04) 273-279
    Google Scholar
  • 14 Shome D, Nair AG, Kapoor R, Jain V. Botulinum toxin A: is it really that fragile a molecule?. Dermatol Surg 2010; 36 (Suppl. 04) 2106-2110
    CrossrefPubMedGoogle Scholar
  • 15 Liu A, Carruthers A, Cohen JL. , et al. Recommendations and current practices for the reconstitution and storage of botulinum toxin type A. J Am Acad Dermatol 2012; 67 (03) 373-378
    CrossrefPubMedGoogle Scholar
  • 16 Jia Z, Lu H, Yang X. , et al. Adverse events of botulinum toxin type A in facial rejuvenation: a systematic review and meta-analysis. Aesthetic Plast Surg 2016; 40 (05) 769-777
    CrossrefPubMedGoogle Scholar
  • 17 Santamato A, Ranieri M, Panza F. , et al. Effectiveness of switching therapy from complexing protein-containing botulinum toxin type A to a formulation with low immunogenicity in spasticity after stroke: a case report. J Rehabil Med 2012; 44 (09) 795-797
    CrossrefPubMedGoogle Scholar
  • 18 Attenello NH, Maas CS. Injectable fillers: review of material and properties. Facial Plast Surg 2015; 31 (01) 29-34
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Kablik J, Monheit GD, Yu L, Chang G, Gershkovich J. Comparative physical properties of hyaluronic acid dermal fillers. Dermatol Surg 2009; 35 (Suppl. 01) 302-312
    CrossrefPubMedGoogle Scholar
  • 20 Kontis TC. Contemporary review of injectable facial fillers. JAMA Facial Plast Surg 2013; 15 (01) 58-64
    CrossrefPubMedGoogle Scholar
  • 21 Lemperle G, Knapp TR, Sadick NS, Lemperle SM. ArteFill permanent injectable for soft tissue augmentation: I. Mechanism of action and injection techniques. Aesthetic Plast Surg 2010; 34 (03) 264-272
    CrossrefPubMedGoogle Scholar
  • 22 Ridenour B, Kontis TC. Injectable calcium hydroxylapatite microspheres (Radiesse). Facial Plast Surg 2009; 25 (02) 100-105
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Moers-Carpi M, Vogt S, Santos BM, Planas J, Vallve SR, Howell DJ. A multicenter, randomized trial comparing calcium hydroxylapatite to two hyaluronic acids for treatment of nasolabial folds. Dermatol Surg 2007; 33 (Suppl. 02) S144-S151
    PubMedGoogle Scholar
  • 24 Dickey RM, Louis MR, Cox JA, Mohan K, Lee EI, Nigro MG. Noninvasive facial rejuvenation. Part 2: Physician-directed-neuromodulators and fillers. Semin Plast Surg 2016; 30 (03) 134-142
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Rzany B, DeLorenzi C. Understanding, avoiding, and managing severe filler complications. Plast Reconstr Surg 2015; 136 (5, Suppl): 196S-203S
    CrossrefPubMedGoogle Scholar
  • 26 Hwang K. Hyperbaric oxygen therapy to avoid blindness from filler injection. J Craniofac Surg 2016; 27 (08) 2154-2155
    CrossrefPubMedGoogle Scholar
  • 27 Philipp-Dormston WG, Bergfeld D, Sommer BM. , et al. Consensus statement on prevention and management of adverse effects following rejuvenation procedures with hyaluronic acid-based fillers. J Eur Acad Dermatol Venereol 2017; 31 (07) 1088-1095
    CrossrefPubMedGoogle Scholar
  • 28 Dubina M, Tung R, Bolotin D. , et al. Treatment of forehead/glabellar rhytide complex with combination botulinum toxin a and hyaluronic acid versus botulinum toxin A injection alone: a split-face, rater-blinded, randomized control trial. J Cosmet Dermatol 2013; 12 (04) 261-266
    CrossrefPubMedGoogle Scholar
  • 29 Beer KR, Julius H, Dunn M, Wilson F. Remodeling of periorbital, temporal, glabellar, and crow's feet areas with hyaluronic acid and botulinum toxin. J Cosmet Dermatol 2014; 13 (02) 143-150
    CrossrefPubMedGoogle Scholar